Therapeutic targets for hypoxia-elicited pathways

Pharmaceutical Research

Volumn 16, Issue 10, 1999, Pages 1498-1505

  Taylor, Cormac T ^a   Colgan, Sean P ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Angiogenesis; Cyclic nucleotide; Ischemia; Lipid mediator; Proteasome; Therapeutics

Indexed keywords

ACETYLSALICYLIC ACID; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; ERYTHROPOIETIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHODIESTERASE INHIBITOR; PROTEINASE INHIBITOR; PROTON PUMP INHIBITOR; THALIDOMIDE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; CELL PROTECTION; DRUG RESEARCH; DRUG TARGETING; ENZYME INHIBITION; GENE THERAPY; HUMAN; HYPOXIA; ISCHEMIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN SYNTHESIS REGULATION; PROTEIN TARGETING; REVIEW; SECOND MESSENGER;

ANIMALS; ANOXIA; HUMANS; SIGNAL TRANSDUCTION;

EID: 0032730930     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011936016833     Document Type: Review

References (96)

1. H. F. Bunn and R. O. Poyton. Oxygen sensing and molecular adaptation to hypoxia. Physiol. Rev. 76 :839-885 (1996).
2. M. Gassmann and R. H. Wenger. HIF-1, a mediator of the molecular response to hypoxia. News Physiol. Sci. 12:214-218 (1997).
3. P. J. Ratcliffe, J. F. O'Rourke, P. H. Maxwell, and C. W. Pugh. Oxygen sensing, hypoxia-inducible factor-I and the regulation of mammalian gene expression. J. Exp. Biol. 201: 1153-1162 (1998).
4. G. L. Semenza. Hypoxia-inducible factor 1: master regulator of O2 homeostasis. Curr. Opin. Genet. Dev. 8:588-94 (1998).
5. P. Saikumar, Z. Dong, J. M. Weinberg, and M. A. Venkatachalam. Mechanisms of cell death in hypoxia/reoxygenation injury. Oncogene 17:3341-9 (1998).
6. G. L. Semenza. Regulation of erythropoietin production. New insights into molecular mechanisms of oxygen homeostasis. Hematol. Oncol. Clin. North Am. 8:863-84 (1994).
7. H. F. Bunn, L. J. Gu, E. Huang, J. W. Park, and H. Zhu. Erythropoietin: a model system for studying oxygen-dependent gene regulation. J. Exp. Biol. 201:1197-1201 (1998).
8. G. L. Semenza and G. L. Wang. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Molec. Cell. Biol. 12:5447-5454 (1992).
9. 2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc. Nat. Acad. Sci. (USA). 95:7987-7992 (1998).
10. G. L. Wang, B. H. Jiang, E. A. Rue, and G. L. Semenza. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular oxygen tension. Proc. Natl. Acad. Sci. USA 92:5510-5514 (1995).
11. G. L. Wang and G. L. Semenza. Purification and characterization of hypoxia-inducible factor 1. J. Biol. Chem. 270:1230-1237 (1995).
12. P. J. Kallio, W. J. Wilson, S. O'Brien, Y. Makino, and L. Poellinger. Regulation of the hypoxia-inducible transcription factor 1 α by the ubiquitin-proteasome pathway. J. Biol. Chem. 274:6519-6525, (1999).
13. G. L. Wang and G. L. Semenza. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc. Nat. Acad. Sci. (USA). 90:4304-4308 (1993).
14. P. H. Maxwell, C. W. Pugh, and P. J. Ratcliffe. Inducible operation of the erythropoietin 3' enhancer in multiple cell lines: evidence for a widespread oxygen-sensing mechanism. Proc. Natl. Acad. Sci. USA 90:2423-2427 (1993).
15. M. V. Blagosklonny, W. G. An, L. Y. Romanova, J. Trepel, T. Fojo, and L. Neckers. p53 inhibits hypoxia-inducible factor-stimulated transcription. J. Biol. Chem. 273: 11995-11998 (1998).
16. Y. Liu, H. Christou, T. Morita, E. Laughner, G. L. Semenza, and S. Kourembanas. Carbon monoxide and nitric oxide supress the hypoxic induction of vascular endothelial growth factor gene via the 5' enhancer. J. Biol. Chem. 273:15257-15262 (1998).
17. K. Sogawa, K. Numayama-Tsuruta, M. Ema, M. Abe, H. Abe, and Y. Fujii-Kuriyama. Inhibition of hypoxia-inducible factorlactivity by nitric oxide doners in hypoxia. Proc. Natl. Acad. Sci. USA 95:7368-7373 (1998).
18. P. Vaupel. Oxygen transport in tumors: characteristics and clinical implications. Adv. Exp. Med. Biol. 388:341-351 (1996).
19. J. F. O'Rourke, G. U. Dachs, J. M. Gleadle, P. H. Maxwell, C. W. Pugh, I. J. Stratford, S. M. Wood, and P. J. Ratcliffe. Hypoxia response elements. Oncol. Res. 9:327-332 (1997).
20. P. H. Maxwell, G. U. Dachs, J. M. Gleadle, L. G. Nicholls, A. L. Harris, I. J. Stratford, O. Hankinson, C. W. Pugh, and P. J. Ratcliffe. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc. Natl. Acad. Sci. USA 94:8104-9 (1997).
21. J. A. Forsythe, B. H. Jiang, N. V. Iyer, F. Agani, S. W. Leung, R. D. Koos, and G. L. Semenza. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol. 16:4604-13 (1996).
22. P. Carmeliet, Y. Dor, J. M. Herbert, D. Fukumura, K. Brusselmans, M. Dewerchin, M. Neeman, F. Bono, R. Abramovitch, P. Maxwell, C. J. Koch, P. Ratcliffe, L. Moons, R. K. Jain, D. Collen, and E. Keshert. Role of HIF-1 alpha in hypoxia-mediated apoptosis, cell proliferation and tumor angiogenesis. Nature 394:485-490 (1998).
23. K. Guillemin and M. Krasnow. The hypoxic response: huffing and HIFing. Cell 89:9-12 (1997).
24. C. J. Gulledge and M. W. Dewhirst. Tumor oxygenation: a matter of supply and demand. Anticancer Res. 16:741-749 (1996).
25. P. J. Barnes and M. Karin. Nuclear factor-κB-A pivitol transcription factor in chronic inflammatory disease. N. Engl. J. Med. 336:1066-1071 (1997).
26. T. Collins, M. A. Read, A. S. Neish, M. Z. Whitley, D. Thanos, and T. Maniatis. Transcriptional regulation of endothelial cell adhesion molecules: NK-κB and cytokine-inducible enhancers. FASEB J. 9:899-909 (1995).
27. A. Pietersma, N. DeJong, J. F. Koster, and W. Sluiter. Effect of hypoxia on adherence of granulocytes to endothelial cells in vitro. Am. J. Physiol. 267:H874-H879 (1994).
28. N. Yoshida, D. N. Granger, D. C. Anderson, R. Rothlein, C. Lane, and P. R. Kvietys. Anoxia/reoxygenation-induced neutrophil adherence to cultured endothelial cells. Am. J. Physiol. 265:H699-H703 (1992).
29. R. Shreeniwas, S. Koga, M. Karakurum, D. Pinsky, E. Kaiser, J. Brett, B. A. Wolitzky, C. Norton, J. Plocinski, W. Benjamin, D. K. Burns, A. Goldstein, and D. Stern. Hypoxia-mediated induction of endothelial cell interleukin-1-α: An autocrine mechanism promoting expresion of leukocyte adhesion molecules on the vessel surface. J. Clin. Invest. 90:2333-2339 (1992).
30. G. Zünd, S. Uezono, G. L. Stahl, A. L. Dzus, F. X. McGowan, P. R. Hickey, and S. P. Colgan. Hypoxia enhances endotoxin-stimulated induction of functional intercellular adhesion molecule-1 (ICAM-1). Am. J. Physiol. 273:C1571-C1580 (1997).
31. G. Zünd, D. P. Nelson, E. J. Neufeld, A. L. Dzus, J. Bischoff, J. E. Mayer, and S. P. Colgan. Hypoxia enhances stimulus-dependent induction of E-selectin on aortic endothelial cells. Proc. Natl. Acad. Sci. USA 93:7075-7080 (1996).
32. J. H. James, C. H. Fang, S. J. Schrantz, P. O. Hasselgren, R. J. Paul, and J. E. Fischer. Linkage of aerobic glycolysis to sodium-potassium transport in rat skeletal muscle. Implications for increased lactate production in sepsis. J. Cliff. Invest. 98:2388-2397 (1996).
33. G. Tiao, S. Hobler, J. J. Wand, T. A. Meyer, F. A. Luchette, J. E. Fischer, and P.-O. Hasslegren. Sepsis is associated with increased mRNA's of the ubiquitin-proteasome proteolytic pathway in human skeletal muscle. J. Clin. Invest. 99:163-168 (1997).
34. M. Montminy. Transcriptional regulation by cyclic AMP. Annu. Rev. Biochem. 66:807-822 (1997).
35. A. V. Tretyakov and H. W. Farber. Endothelial cell tolerance to hypoxia: Potential role of purine nucleotide phosphates. J. Clin. Invest. 95:738-744 (1995).
36. S. Ogawa, S. Koga, K. Kuwabara, J. Brett, B. Morrow, S. A. Morris, J.P. Bilezikian, S.C. Silverstein, and D. Stern. Hypoxia-induced increased permeability of endothelial monolayers occurs through lowering of cellular cAMP levels. Am. J. Physiol. 262:C546-C554 (1992).
37. R. Shreeniwas, S. Ogawa, F. Cozzolino, G. Torcia, N. Braunstein, C. Butura, J. Brett, H. B. Leiberman, M. B. Furie, J. Joseph-Silverstien, and D. Stern. Macrovascular and microvascular endothelium during long-term hypoxia: Alterations in cell growth, monolayer permeability, and cell surface coagulant properties. J. Cell. Physiol. 146:8-17 (1991).
38. S. Ogawa, R. Shreeniwas, C. Butura, J. Brett, and D. Stern. Modulation of endothelial barrier function by hypoxia: Perturbation of barrier and anticoagulant function, and induction of a novel factor X activator. Adv. Exp. Med. Biol. 281:303-312 (1990).
39. D. J. Pinsky, M. C. Oz, H. Liao, S. Morris, J. Brett, A. Morales, M. Karakurum, M. M. V. L. Campagne, R. Nowygrod, and D. M. Stern. Restoration of the cAMP second messenger pathway enhances cardiac preservation for transplantation in a heterotopic rat model. J. Clin. Invest. 92:2994-3002 (1993).
40. C. T. Taylor, S. J. Lisco, C. S. Awtrey, and S. P. Colgan. Hypoxia inhibits cyclic nucleotide-stimulated epithelial ion transport: role for nucleotide cyclases as oxygen sensors. J. Pharmacol. Exp. Ther. 284:568-575 (1998).
41. G. B. Friedman, C. T. Taylor, C. A. Parkos, and S. P. Colgan. Epithelial permeability induced by neutrophil transmigration is potentiated by hypoxia: role of intracellular cAMP. J. Cell. Physiol. 176:76-84 (1998).
42. C. T. Taylor, N. Fueki, A. Agah, R. M. Hershberg, and S. P. Colgan. Critical role of cAMP response element binding protein expression in hypoxia-elicited induction of epithelial TNFα. J. Biol. Chem. 274:19447-19450 (1999).
43. I. Kvietikova, R. H. Wenger, H. H. Marti, and M. Gassmann. The hypoxia-inducible factor-1 DNA recognition site is cAMP responsive. Kid. Int. 51:564-566 (1997).
44. R. Tazawa, X. M. Xu, K. K. Wu, and L. H. Wang. Characterization of the genomic structure, chromosomal location and promoter of human prostaglandin H synthase-2 gene. Biochem. Biophys. Res. Commun. 203:190-9 (1994).
45. J. F. Schmedtje, Y. S. Ji, W. L. Liu, R. N. DuBois, and M. S. Runge. Hypoxia induces cyclooxygenase-2 via the NF-kappaB p65 transcription factor in human vascular endothelial cells. J. Biol. Chem. 272:601-608 (1997).
46. lu is an epithelial secretagogue. J. Clin. Invest. 102:1161-1172 (1998).
47. R. Wadgaonkar, K. M. Phelps, Z. Haque, A. J. Williams, E. S. Silverman, and T. Collins. CREB-binding protein is a nuclear integrator of nuclear factor-kappaB and p53 signaling. J. Biol. Chem. 274: 1879-82 (1999).
48. C. T. Taylor, A. L. Dzus, and S. P. Colgan. Autocrine regulation of intestinal epithelial permeability induced by hypoxia: Role for basolateral release of tumor necrosis factor-α (TNF-α). Gastroenterology 114:657-668 (1998).
49. C. Wahl, S. Liptay, G. Adler, and R. M. Schmid. Sulfasalazine: a Potent and specific inhibitor of nuclear factor kappa B. J. Clin. Invest. 101:1163-74 (1998).
50. E. Kopp and S. Ghosh. Inhibition of NF-κB by sodium salicylate and aspirin. Science 265:956-959 (1994).
51. D. H. Lee and A. L. Goldberg. Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell. Biol. 8:397-403 (1998).
52. M. Rolfe, M. I. Chiu, and M. Pagano. The ubiquitin-mediated proteolytic pathway as a therapeutic area. J. Mol. Med. 75:5-17 (1997).
53. G. Fenteany and S. L. Schreiber. Lactacystin. proteasome function, and cell fate. J. Biol. Chem. 273:8545-8 (1998).
54. M. S. O'Reilly, T. Boehm, Y. Shing, N. Fukai, G. Vasios, W. S. Lane, E. Flynn, J. R. Birkhead, B. R. Olsen, and J. Folkman. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277-285 (1997).
55. M. S. O'Reilly, L. Holmgren, C. Chen, and J. Folkman. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat. Med. 2:689-92 (1996).
56. P. H. Maxwell, M. S. Wiesener, G. W. Chang, S.C. Clifford, E. C. Vaux, M. E. Cockman, C. C. Wykoff, C. W. Pugh, E. R. Maher, and P. J. Ratcliffe. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399:271-5 (1999).
57. K. H. Plate, G. Breier, H. A. Weich, and W. Risau. Vascular endothelial growth factor is a potential tumor angiogenesis factor in human gliomas in vivo. Nature 359:845-847 (1992).
58. G. Molema, D. K. Meijer, and L. F. de Leij. Tumor vasculature targeted therapies: getting the players organized. Biochem. Pharmacol. 55:1939-1945. (1998).
59. I. Zachary. Vascular endothelial growth factor. Int. J. Biochem. Cell. Biol. 30:1169-1174 (1998).
60. T. Kanai, H. Konno, T. Tanaka, M. Baba, K. Matsumoto, S. Nakamura, A. Yukita, M. Asano, H. Suzuki, and S. Baba. Anti-tumor and anti-metastatic effects of human-vascular-endothelial-growth-factor-neutralizing antibody on human colon and gastric carcinoma xenotransplanted orthotopically into nude mice. Int. J. Cancer. 77:933-936 (1998).
61. L. W. Chen, C. M. Hsu, J. S. Wang, J. S. Chen, and S.C. Chen. Specific inhibition of iNOS decreases the intestinal mucosal peroxynitrite level and improves the barrier function after thermal injury. Burns 24:699-705 (1998).
62. G. J. Southan and C. Szabo. Selective pharmacological inhibition of distinct nitric oxide synthase isoforms. Biochem. Pharmacol. 51:383-394 (1996).
63. L. L. Thomsen and D. W. Miles. Role of Nitric Oxide in tumor progression: lessons from human tumors. Cancer Metastesis. Rev. 17:107-118 (1998).
64. R. J. D'Amato, M. S. Loughnan, E. Flynn, and J. Folkman. Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. USA 91:4082-5 (1994).
65. L. G. Corral, G. W. Muller, A. L. Moriera, Y. Chen, M. Wu, D. Stirling, and G. Kaplan. Selection of novel analogs of thalidomide with enhanced tumor necrosis factor inhibitory activity. Mol. Med. 2:506-515 (1996).
66. E. C. Svensson and L. B. Schwartz. Gene therapy for vascular disease. Curr. Opin. Cardiol. 13:369-74 (1998).
67. J. M. Isner. Vascular endothelial growth factor: gene therapy and therapeutic angiogenesis. Am. J. Cardiol. 82:63S-64S (1998).
68. D. J. Pinsky, Y. Naka, N. C. Chowdhury, H. Liao, M. C. Oz, R. E. Michler, E. Kubaszewski, T. Malinski, and D. M. Stern. The nitic oxide/cyclic GMP pathway in organ transplantation: critical role in successful lung preservation. Proc. Natl. Aced. Sci. (USA). 91:12086-12090 (1994).
69. M. C. Oz, D. J. Pinsky, S. Koga, H. Liao, C. C. Marboe, D. Han, R. Kline, V. Jeevanandam, M. Williams, A. Morales, S. Popilskis, R. Nowygrod, D. Stern, E. Rose, and R. Michler. Novel preservation solution permits 24-hour preservation in rat and baboon cardiac transplant models. Circulation 88:291-7 (1993).
70. C. N. Serhan, J. Z. Haeggstrom, and C. C. Leslie. Lipid mediator networks in cell signaling: update and impact of cytokines. FASEB J. 10:1147-1158 (1996).
71. C. N. Serhan. Lipoxin biosynthesis and its impact in inflammatory and vascular events. Biochim. et Biophys. Acta. 1212:1-25 (1994).
72. J. Claria and C. N. Serhan. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc. Natl. Acad. Sci. (USA). 92:9475-9479 (1995).
73. 4 stable analogs that block human neutrophil transmigration and adhesion. Biochemistry USA. 34:14609-14615 (1995).
74. J. Claria, M. H. Lee, and C. N. Serhan. Aspirin-triggered lipoxins (15-epi-LX) are generated by the human lung adenocarcinoma cell line (A549)-neutrophil interactions and are potent inhibitors of cell proliferation. Mol. Med. 2:583-596 (1996).
75. G. Ricevuti. Host tissue damage by phagocytes. Ann. NY Acad. Sci. 832:426-48 (1997).
76. C. R. B. Welbourne, G. Goldman, C. R. Valeri, D. Shepro, and H. B. Hechtman. Pathophysiology of ischaemia reperfusion injury: central role of the neutrophil. Br. J. Surg. 78:651-655 (1991).
77. C. A. Parkos. Molecular events in neutrophil transepithelial migration. BioEssays 19:865-873 (1997).
78. T. A. Springer. Adhesion receptors of the immune system. Nature 346:425-430 (1990).
79. M. Karakurum, R. Shreeniwas, J. Chen, D. Pinsky, S.-D. Yan, M. Anderson, K. Sunouchi, J. Major, T. Hamilton, K. Kuwabara, A. Rot, R. Nowygrod, and D. Stern. Hypoxic induction of interleukin-8 gene expression in human endothelial cells. J. Clin. Invest. 93:1564-1570 (1994).
80. S. P. Colgan, A. L. Dzus, and C. A. Parkos. Epithelial exposure to hypoxia modulates neutrophil transepithelial migration. J. Exp. Med. 184:1003-1015 (1996).
81. 4 modulates transmigration of human neutrophils across intestinal epithelial monolayers. J. Clin. Invest. 92:75-82 (1993).
82. 4 analogs. J. Clin. Invest. 101:1860-1869 (1998).
83. 4 analogs with increased biologic activity. FASEB J. 12:487-494 (1998).
84. 4. In: Cell-Cell Interactions in the Release of Inflammatory Mediators, edited by P. Y.-K. Wong and C. N. Serhan. New York: Plenum Press, 185-192, 1991.
85. S. E. Dahlen, L. Franzen, J. Raud, C. N. Serhan, P. Westlund, E. Wikstrom, T. Bjorck, H. Matsuda, S. E. Webber, C. A. Veale, and a. et. Actions of lipoxin A4 and related compounds in smooth muscle preparations and on the microcirculation in vivo. Adv. Exp. Med. Biol. 229:107-30(1988).
86. T. Takano, C. B. Clish, K. Gronert, N. Petasis, and C. N. Serhan. Neutrophil-mediated changes in vascular permeability are inhibited by topical application of aspirin-triggered 15-epi-lipoxin A4 and novel lipoxin B4 stable analogues. J Clin Invest. 101:819-26 (1998).
87. W. Makarewicz. Response of purine metabolism to hypoxia and ischemia. Adv. Exp. Med. Biol. 431:351-7 (1998).
88. B. N. Cronstein. Adenosine, an endogenous anti-inflammatory agent. J. Appl. Physiol. 76:5-13 (1994).
89. X. Zhou, X. Zhai, and M. Ashraf. Preconditioning of bovine endothelial cells. The protective effect is mediated by an adenosine A2 receptor through kinase signaling pathway. Circ. Res. 78:73-81 (1996).
90. R. de Jonge, S. Bradamante, and J. W. de Jong. Cardioprotection by ischemic preconditioning. Role of adenosine and glycogen. Adv. Exp. Med. Biol. 431:279-82 (1998).
91. L. Airas, J. Niemela, M. Salmi, T. Puurunen, D. J. Smith, and S. Jalkanen. Differential regulation and function of CD73, a glycosyl-phosphatidylinositol-linked 70-kD adhesion molecule, on lymphocytes and endothelial cells. J. Cell Biol. 136:421-431 (1997).
92. T. Minamino, M. Kitakaze, T. Morioka, K. Node, K. Komamura, H. Takeda, M. Inoue, M. Hori, and T. Kamada. Cardioprotection due to preconditioning correlates with increased ecto-5′-nucleotidase activity. Am. J. Physiol. 270:H238-44 (1996).
93. T. Kaji, M. Inada, C. Yamamoto, Y. Fujiwara, and F. Koizumi. Cyclic AMP-dependent pathway that mediates suppressive regulation of glycosaminoglycan production in cultured vascular endothelial cells. Thromb. Res. 82:389-97 (1996).
94. M. M. Burein, G. Schiedner, S. Kochanek, S. Y. Tsai, and B. W. O'Malley. Adenovirus-mediated regulable target gene expression in vivo. Proc. Natl. Acad. Sci. USA 96:355-60 (1999).
95. X. Ye, V. M. Rivera, P. Zoltick, F. Cerasoli Jr., M. A. Schnell, G. Gao, J. V. Hughes, M. Gilman, and J. M. Wilson. Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer. Science 283:88-91 (1999).
96. H. Prentice, N. H. Bishopric, M. N. Hicks, D. J. Discher, X. Wu, A. A. Wylie, and K. A. Webster. Regulated expression of a foreign gene targeted to the ischaemic myocardium. Cardiovasc. Res. 35:567-74 (1997).